2008
DOI: 10.1097/coh.0b013e32830b0f4c
|View full text |Cite
|
Sign up to set email alerts
|

Microbicide safety and effectiveness: an overview of recent clinical trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2009
2009
2012
2012

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 60 publications
(48 reference statements)
0
1
0
Order By: Relevance
“…Products previously tested in clinical trials demonstrated mixed efficacy results, including the most recent positive development [8,9] with a 1% vaginal gel formulation of tenofovir, which reduced HIV acquisition in South African women by 39% overall and by 54% among those with high gel adherence [10,11]. UC781 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of the HIV-1 reverse transcriptase (RT) enzyme which has the potential to act against a wide range of HIV-1 isolates, including laboratory adapted strains and primary isolates of all major clades (A through G).…”
Section: Introductionmentioning
confidence: 99%
“…Products previously tested in clinical trials demonstrated mixed efficacy results, including the most recent positive development [8,9] with a 1% vaginal gel formulation of tenofovir, which reduced HIV acquisition in South African women by 39% overall and by 54% among those with high gel adherence [10,11]. UC781 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of the HIV-1 reverse transcriptase (RT) enzyme which has the potential to act against a wide range of HIV-1 isolates, including laboratory adapted strains and primary isolates of all major clades (A through G).…”
Section: Introductionmentioning
confidence: 99%